Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).

September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File (DMF) to the U.S. Food and Drug Administration for GalliaPharm. Their proprietary Ge-68/Ga-68 generator from now on will additionally be available in sizes of up to 100 mCi with a shelf-life of 12 months or for a maximum of 700 elutions. Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).

“With the development of generators with higher Ge-68 activity and the amendment of our DMF, we are responding to the increasing demand for Ga-68 based diagnostics in the United States,” explained Dr Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment. “The soon to be available preparations for imaging of prostate cancer as well as upcoming novel Ga-68 drugs and their theranostic pair, mostly labeled with Lu-177, allow Eckert & Ziegler to strongly support the trend towards higher activity generators and we are currently working to provide comprehensive solutions to the healthcare providers and their patients.”

“Higher activity GalliaPharm generators will enable nuclear medicine institutions and radiopharmacies across the United States to prepare their Ga-68 PET imaging products with the same flexibility as they are used to, while being able to offer the procedures to a greater number of patients and with an expanded service area,“ added Jay Simon, General Manager of Eckert & Ziegler Radiopharma, Inc. in Wilmington, MA. “Users can obtain additional doses from a single generator elution and are at the same time able to significantly increase the number of daily elutions. Both will contribute to enhanced medical care and assure the supply to American patients.”

GalliaPharm is mainly used in combination with tracer kits for diagnosis of neuroendocrine tumors and prostate cancer. Gallium generators offer a low-cost alternative for the radiolabeling of biomolecules with Gallium-68 in PET, an imaging examination method used to detect the presence or absence of diseased tissue. PET imaging is primarily used in the diagnosis of cancer, cardiology or neurology. Radioisotopes such as Fluorine-18 can be used alternatively but require investments of millions of dollars in large-scale equipment (cyclotrons). The Ge-68/Ga-68 generator on the other hand, is an easily transportable, small system that is much more cost-efficient, leading to cost reductions for nuclear medicine providers while increasing flexibility.

For more information: www.medical.ezag.com


Related Content

News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Over the past several years, technological advancements have driven the development of more precise and targeted ...

Time January 16, 2024
arrow
Subscribe Now